STOCK TITAN

Oncolytics Biotech, Inc. Common Shares - ONCY STOCK NEWS

Welcome to our dedicated page for Oncolytics Biotech Common Shares news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech Common Shares stock.

Oncolytics Biotech Inc. (symbol: ONCY) is a pioneering biotechnology company dedicated to the development of oncolytic viruses as innovative cancer therapeutics. Their flagship product, pelareorep, is a unique immunotherapeutic agent designed to harness the power of the human reovirus to enhance the body's immune response against cancer. Pelareorep has shown promising potential in making tumors more responsive to a variety of oncology treatments by promoting an inflamed tumor phenotype.

The company's robust clinical development pipeline includes multiple human trials targeting some of the most prevalent cancers, such as breast, gastrointestinal, and pancreatic cancers. Notably, Oncolytics is conducting a Phase III trial for head and neck cancers and has several ongoing trials in advanced stages, including the GOBLET study, which explores the efficacy of pelareorep in combination with different chemotherapy regimens.

In breast cancer, Oncolytics is advancing towards registration-enabling studies for HR+/HER2- metastatic breast cancer, supported by compelling data from the BRACELET-1 and IND-213 randomized studies. The company is also making significant strides in pancreatic cancer research, recently receiving a US$5 million grant from the Pancreatic Cancer Action Network (PanCAN) for a new Phase 1/2 cohort in the GOBLET study, assessing pelareorep in combination with modified FOLFIRINOX and atezolizumab (Tecentriq®).

Financially, Oncolytics is well-positioned with a strong balance sheet and ongoing support from strategic partnerships and grants. The company’s collaborations with leading research institutions and oncology networks enhance its clinical programs and accelerate the development of pelareorep as a versatile cancer therapy. Oncolytics continues to innovate and push the boundaries of cancer treatment, aiming to bring new hope to patients worldwide.

Rhea-AI Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented translational data from the AWARE-1 breast cancer study at the San Antonio Breast Cancer Symposium. The data showed that pelareorep induced the expansion of Tumor Infiltrating Lymphocytes (TILs) in the blood and new TILs in the tumor, affirming its role as an immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announces positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA). The interim objective response rate (ORR) of 37.5% exceeded historical control trials, showing the potential for pelareorep to offer a new, effective treatment option for patients with advanced SCCA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
-
Rhea-AI Summary
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC). The company will conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study. PanCAN will grant US$5 million for the new Phase 2 GOBLET study arm evaluating the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) in pancreatic cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.92%
Tags
none
Rhea-AI Summary
Oncolytics Biotech announces positive translational data from the AWARE-1 breast cancer study, confirming pelareorep's mechanism of action in the tumor microenvironment. The data shows an increase in PD-L1 positive cells and T cell infiltration after treatment. This supports the use of pelareorep in combination with atezolizumab for metastatic breast cancer and other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech announced positive Phase 1/2 survival data for pelareorep in pancreatic cancer. The data showed an objective response rate of 62%, median progression-free survival of 7.2 months, and interim median overall survival of 10.6 months. The company also received a $5 million grant from Pancreatic Cancer Action Network to further evaluate pelareorep in pancreatic cancer. The cash position is $40.0 million with a projected cash runway through critical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
-
Rhea-AI Summary
Oncolytics Biotech announces positive results from the Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma (PDAC) at ESMO 2023. The study shows an overall response rate of 62%, median progression-free survival of 7.2 months, and interim median overall survival of 10.6 months. T-cell expansion data correlate with tumor response. The treatment combination has been well tolerated with no safety concerns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
Rhea-AI Summary
Oncolytics Biotech announces positive interim results from the Phase 1/2 GOBLET study evaluating pelareorep in patients with third-line metastatic colorectal cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
none
-
Rhea-AI Summary
Oncolytics Biotech to host conference call and webcast on November 3, 2023, to discuss corporate update and financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
conferences earnings
-
Rhea-AI Summary
Oncolytics Biotech announces the publication of two abstracts for posters to be presented at the ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
Rhea-AI Summary
Oncolytics Biotech receives $5 million grant from PanCAN for pancreatic cancer research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
none

FAQ

What is the current stock price of Oncolytics Biotech Common Shares (ONCY)?

The current stock price of Oncolytics Biotech Common Shares (ONCY) is $0.98 as of November 21, 2024.

What is the market cap of Oncolytics Biotech Common Shares (ONCY)?

The market cap of Oncolytics Biotech Common Shares (ONCY) is approximately 75.5M.

What is Oncolytics Biotech Inc. known for?

Oncolytics Biotech Inc. is known for developing pelareorep, an innovative oncolytic virus used as a potential cancer therapeutic to enhance the immune system's response to tumors.

What cancers is Oncolytics currently targeting?

Oncolytics is targeting a variety of cancers including breast, gastrointestinal, pancreatic, and head and neck cancers through its clinical trials and research programs.

What is pelareorep?

Pelareorep is Oncolytics Biotech’s proprietary formulation of the human reovirus, designed to stimulate immune responses and make tumors more susceptible to a range of oncology treatments.

What are the recent achievements of Oncolytics Biotech?

Recent achievements include advancing to Phase III trials in head and neck cancers, receiving a US$5 million grant for pancreatic cancer research, and positive Phase 2 data in metastatic breast cancer.

How is Oncolytics Biotech funded?

Oncolytics Biotech is funded through a mix of strategic partnerships, grants, and a robust cash position to support its clinical development programs and operations.

What is the GOBLET study?

The GOBLET study is a Phase 1/2 clinical trial exploring the efficacy of pelareorep in combination with chemotherapy and checkpoint inhibitors in gastrointestinal cancers, particularly pancreatic cancer.

What are the potential benefits of pelareorep?

Pelareorep has demonstrated potential benefits such as enhancing the immune system's ability to fight cancer, increasing tumor susceptibility to treatments, and promoting an inflamed tumor phenotype.

What is the focus of Oncolytics' current clinical trials?

Oncolytics' clinical trials focus on leveraging pelareorep in combination with various chemotherapy regimens and immunotherapies to treat multiple cancer types effectively.

What partnerships does Oncolytics Biotech have?

Oncolytics partners with leading research institutions, oncology networks, and pharmaceutical companies to accelerate the development and commercialization of its therapies.

Where can I find more information about Oncolytics Biotech?

More information about Oncolytics Biotech can be found on their official website at www.oncolyticsbiotech.com or through their social media channels on LinkedIn and X (formerly Twitter).

Oncolytics Biotech, Inc. Common Shares

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

75.53M
74.22M
3.82%
1.76%
3.66%
Biotechnology
Healthcare
Link
United States of America
Calgary